Xeomin(®), a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury

Xeomin(®) is a commercial formulation of botulinum neurotoxin type A (BoNT/A) clinically authorized for treating neurological disorders, such as blepharospasm, cervical dystonia, limb spasticity, and sialorrhea. We have previously demonstrated that spinal injection of laboratory purified 150 kDa BoN...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastrorilli, Valentina, De Angelis, Federica, Vacca, Valentina, Pavone, Flaminia, Luvisetto, Siro, Marinelli, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142820/
https://www.ncbi.nlm.nih.gov/pubmed/37104185
http://dx.doi.org/10.3390/toxins15040248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142820/
https://www.ncbi.nlm.nih.gov/pubmed/37104185
http://dx.doi.org/10.3390/toxins15040248

Ejemplares similares